

PRECIGEN

44th Annual J.P. Morgan
Healthcare Conference

January 15, 2026

NASDAQ: PGEN



Forward-looking Statements

This presentation contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company’s business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company’s ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and the Company’s other product candidates, the timing of clinical trials and their results, the Company’s ability to commence clinical studies or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

PRECIGEN

ADVANCING MEDICINE WITH PRECISION®

Precigen is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need.

HEADQUARTERS

Germantown, MD

NASDAQ

PGEN

US EMPLOYEES

~140

AS OF DEC. 2025

YEAR FOUNDED

2020

[precigen.com](https://www.precigen.com)



APPROACH

Precigen's approach unites cutting-edge technology, precise indication selection, and smart regulatory pathways to bring breakthrough therapies to patients with infectious diseases, rare diseases, and cancer.

VISION

Precigen's vision is to develop life-changing and cost-conscious therapies utilizing our cutting-edge therapeutic and platform technologies for patients with high unmet medical need.


PRECIGEN

AdenoVerse®

Novel, Industry-Leading Viral Vector Platform

Product	Target	Indication	Phase 1	Phase 2	Phase 3	Approved
PAPZIMEOS™	HPV 6/11	RRP	[Progress bar spanning Phase 1, 2, and 3]			
PRGN-2009 (+pembrolizumab)	HPV 16/18	OPSCC/ Head & Neck Cancer	[Progress bar spanning Phase 1 and 2]			
PRGN-2009 (+pembrolizumab)	HPV 16/18	R/M Cervical Cancer	[Progress bar spanning Phase 1 and 2]			

Significant potential in rare diseases and oncology
Wholly-owned IP for AdenoVerse platform and assets




**Underpinned by innovative,
 proprietary AdenoVerse® platform**

**Novel platform to train and amplify the immune
 system in vivo (from WITHIN the body)**

ADVANTAGES

- Large payload capacity
- Low seroprevalence in humans
- Ability for repeat administration
- Durable antigen-specific immune response
- Highly productive manufacturing process



2025: A Transformational Year for Precigen – Now a Commercial- Stage Biotech

1

Full FDA-approval for PAPZIMEOS for the treatment of all adults with RRP regardless of disease severity



2

Commenced commercial US launch of PAPZIMEOS



3

Launched the commercial manufacturing campaign for PAPZIMEOS



4

First commercial sale of PAPZIMEOS



5


Secured up to \$125M in non-dilutive funding to fortify balance sheet



The Only FDA-approved Option for Adults with Recurrent Respiratory Papillomatosis (RRP)

- RRP is a rare, debilitating disease of the respiratory tract caused by HPV 6 or HPV 11 infection
- RRP was previously managed mainly by surgical interventions; repeat surgeries are associated with significant morbidities
- RRP can cause severe voice disturbance, airway compromise, fatal pulmonary lesions, and invasive cancers and is potentially life-threatening


papillomas
(benign tumors)



"I'm delighted to say that the FDA-approved this drug. For the first time in my life, there is a non-surgical option for recurrent respiratory papilloma...We patients are very fortunate to have dedicated and passionate people working to help us."

- PAPZIMEOS clinical trial patient

PAPZIMEOS: From IND in 2021 to Full FDA Approval in 2025



Note: IND=investigational new drug application; ODD=orphan drug designation; BTDRRP=Breakthrough Therapy Designation; FDA=Food and Drug Administration; P1=Phase 1; P2=Phase 2; RRP=recurrent respiratory papillomatosis; BLA=biologics license application; ASCO=2024 American Society of Clinical Oncology Meeting; EU=European Union.



First-and-only FDA-approved therapy for the treatment of adults with RRP

First-and-only FDA-approved RRP treatment to target underlying cause of disease

Chronic, debilitating rare disease with high unmet need


Transformative clinical benefit

Ability to be utilized across different sites of care

PAPZIMEOS has the potential to be the standard of care for adults with RRP


PAPZIMEOS

Pivotal Clinical Data




PAPZIMEOS Targets the Root Cause of RRP

- Ability for repeat injections
- Designed to generate an immune response directed against papilloma cells expressing HPV 6 or HPV11




PAPZIMEOS Has Demonstrated Robust Clinical Data to Date as Evidenced by Durable Ongoing Responses

Efficacy: 51% Complete Response Rate



Durable, Ongoing Complete Responses



As of September 19, 2025, data cutoff:

- Median duration of follow-up at 36 months (27-37)
- Median duration of complete response has yet to be reached

Complete Response: No need for surgery for 12 months after PAPZIMEOS treatment completion
 Note: One subject was excluded as they did not complete 12 months of follow-up
 Sources: PAPZIMEOS Prescribing Information; Norberg SM et al., 2024 ASCO Annual Meeting

Duration of response is the time from completion of zopapogene imadenovec-drba treatment until the date of first surgery or date of last visit with no surgery

Papzimeos™

zopapogene imadenovec-drba

Commercial Opportunity and Launch Momentum



The Prevalence of RRP in the US and Rest of World Suggests Multi-billion-dollar Revenue Potential

Prevalence of RRP in US¹

Approximately

27,000

adult patients
in US



\$1 Billion+
peak revenue opportunity

Prevalence of RRP ex-US²

Approximately

35,000

adults in EU 4,
UK and Japan



Approximately

50,000

adults in rest of EU and
select markets*



Approximately

85,000

adults in
China



\$1 Billion+
peak revenue opportunity

¹ Precigen-commissioned research; analysis derived from claims and Electronic Health Record data

² Precigen-commissioned research and analysis

* Includes Brazil, Mexico, Saudi Arabia, Australia and Canada

Strong Indicators of Success to Support a Successful Launch

Pre-approval

Confirm market opportunity



Claims and EHR analysis identified
~27,000 patients in the US



**Optimize footprint/
targeting**



Pre-approval deployment of **Medical, Payer**
and **Sales Leadership** teams



**Build awareness
and anticipation**



Extensive **PIE process, Disease State Awareness**
and **Scientific Exchange/ Congress** presence



Set up distribution




Specialty Distribution/Pharmacy channels
for full flexibility to providers




Strong Indicators of Success to Support a Successful Launch

Post-approval




Significant Increase in PAPZIMEOS Brand Awareness Since Approval Across Academic and Community Settings

Unaided Awareness of PAPZIMEOS



- Rapid increase in unaided brand awareness
- Seen across academic and community settings
- Reflective of the sense of urgency in the need for a new standard of care



Looking Ahead

2026: Anticipated Milestones for the Year Ahead

Continue execution and expansion to maximize PAPZIMEOS market opportunity and achieve positive cash flow in 2026

PAPZIMEOS regulatory expansion to the EU and Japan

Initiate PAPZIMEOS pediatric RRP study in the US to support label expansion

Platform expansion through PRGN-2009 in head and neck and cervical cancers

PRECIGEN

PAPZIMEOS, the first-and-only FDA-approved product for RRP, launched in the US, with blockbuster potential

Advancing PAPZIMEOS towards regulatory approval ex-US

De-risked technology platform; advancing portfolio of additional oncology and rare disease indications

Leadership team with a proven track record of success through discovery, development, regulatory strategy, and commercialization


Strong balance sheet and capital efficient operating model

Strong Foundation for Long-term Value Creation

Papzimeos™

zopapogene imadenovec-drba

Q&A





PRECIGEN